Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Management in Intertrochanteric Fractures: A Randomized Controlled Study

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2024 Jun 14

PMID 38875178

Authors

Chunyong Zhu

Zhongqing Ji

Jiangfeng Zhu

Hao Xu

Shiyan Li

Chuancheng Liu

Bin Wei

Affiliations

Soon will be listed here.

Abstract

BACKGROUND This prospective study from a single center aimed to compare the perioperative blood loss (PBL) in 79 patients with intertrochanteric fractures (IF) treated with intramedullary nailing (IMN) using 3 regimens of combined tranexamic acid (TXA) and low molecular weight heparin (LMWH), proposing a novel therapy of 4-dose TXA. MATERIAL AND METHODS We recruited 79 patients and randomly divided them into 3 groups. The 4-dose TXA group (22 patients) received 1.0 g intravenous TXA 30 min before surgery and 1.0 g at intervals of 3, 6, and 9 h before surgery. The 1-dose TXA group (25 patients) received 1.0 g intravenous TXA 30 min before surgery, while the control group (32 patients) did not receive TXA. LMWH was applied 12 h after surgery in each group. The primary metrics evaluated included hidden blood loss (HBL), total blood loss (TBL), and the number and incidence rate of deep vein thrombosis (DVT). RESULTS Analysis of the HBL revealed that the 4-dose TXA group had the lowest average (583.13±318.08 ml), followed by the 1-dose TXA group (902.94±509.99 ml), and the control group showed the highest (1154.39±452.06 ml) (P<0.05). A similar result was observed for TBL (4-dose group: 640.86±337.22 ml, 1-dose group: 971.74±511.14 ml, control group: 1226.27±458.22 ml, P<0.05). Regarding DVT, the 4-dose TXA group had 5 cases (incidence rate 22.73%), the 1-dose TXA group had 6 cases (incidence rate 24.00%), and the control group had 8 cases (incidence rate 25.00%), with no significant difference among groups (P>0.05). CONCLUSIONS Treatment using 4-dose TXA and LMWH can effectively reduce PBL without increasing the DVT risk in IF patients with IMN.

References

Fillingham Y, Ramkumar D, Jevsevar D, Yates A, Bini S, Clarke H . Tranexamic Acid Use in Total Joint Arthroplasty: The Clinical Practice Guidelines Endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip.... J Arthroplasty. 2018; 33(10):3065-3069. DOI: 10.1016/j.arth.2018.08.002. View

Gross J . Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983; 58(3):277-80. DOI: 10.1097/00000542-198303000-00016. View

Moran J, Kahan J, Morris J, Joo P, OConnor M . Tranexamic Acid Administration at Hospital Admission Decreases Transfusion Rates in Geriatric Hip Fracture Patients Undergoing Surgery. Geriatr Orthop Surg Rehabil. 2022; 13:21514593221124414. PMC: 9445454. DOI: 10.1177/21514593221124414. View

Picetti R, Shakur-Still H, Medcalf R, Standing J, Roberts I . What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis. 2018; 30(1):1-10. PMC: 6365258. DOI: 10.1097/MBC.0000000000000789. View

Zhou X, Zhang Y, Jiang L, Zhang J, Zhou D, Wu L . Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial. Orthop Surg. 2019; 11(4):635-642. PMC: 6712408. DOI: 10.1111/os.12511. View

Chen Y, Chen Z, Cui S, Li Z, Yuan Z . Topical versus systemic tranexamic acid after total knee and hip arthroplasty: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95(41):e4656. PMC: 5072927. DOI: 10.1097/MD.0000000000004656. View

Cooper C, Cole Z, Holroyd C, Earl S, Harvey N, Dennison E . Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011; 22(5):1277-88. PMC: 3546313. DOI: 10.1007/s00198-011-1601-6. View

Ker K, Edwards P, Perel P, Shakur H, Roberts I . Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012; 344:e3054. PMC: 3356857. DOI: 10.1136/bmj.e3054. View

Liu S, Li C, Zhang P . Enhanced recovery after surgery for hip fractures: a systematic review and meta-analysis. Perioper Med (Lond). 2021; 10(1):31. PMC: 8436561. DOI: 10.1186/s13741-021-00201-8. View

10.

Kanis J, Oden A, McCloskey E, Johansson H, Wahl D, Cooper C . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012; 23(9):2239-56. PMC: 3421108. DOI: 10.1007/s00198-012-1964-3. View

11.

Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E . Guideline for the management of hip fractures 2020: Guideline by the Association of Anaesthetists. Anaesthesia. 2020; 76(2):225-237. DOI: 10.1111/anae.15291. View

12.

Kristiansson J, Hagberg E, Nellgard B . The influence of time-to-surgery on mortality after a hip fracture. Acta Anaesthesiol Scand. 2019; 64(3):347-353. DOI: 10.1111/aas.13494. View

13.

Fischer H, Maleitzke T, Eder C, Ahmad S, Stockle U, Braun K . Management of proximal femur fractures in the elderly: current concepts and treatment options. Eur J Med Res. 2021; 26(1):86. PMC: 8335457. DOI: 10.1186/s40001-021-00556-0. View

14.

Zhang S, Xiao C, Yu W, Long N, He F, Cai P . Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: a randomized controlled trial. Eur J Trauma Emerg Surg. 2020; 48(2):731-741. DOI: 10.1007/s00068-020-01387-0. View

15.

Fillingham Y, Ramkumar D, Jevsevar D, Yates A, Shores P, Mullen K . The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty. 2018; 33(10):3070-3082.e1. DOI: 10.1016/j.arth.2018.03.031. View

16.

Nikolaou V, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis G . Infographic: Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021; 103-B(3):440-441. DOI: 10.1302/0301-620X.103B3.BJJ-2021-0172. View

17.

Schroeder J, Turner S, Buck E . Hip Fractures: Diagnosis and Management. Am Fam Physician. 2022; 106(6):675-683. View

18.

Axelrod D, Gazendam A, Ghert M . The Surgical Management of Proximal Femoral Metastases: A Narrative Review. Curr Oncol. 2021; 28(5):3748-3757. PMC: 8534449. DOI: 10.3390/curroncol28050320. View

19.

Grassin-Delyle S, Semeraro M, Lamy E, Urien S, Runge I, Foissac F . Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth. 2022; 128(3):465-472. DOI: 10.1016/j.bja.2021.10.054. View

20.

Cui Y, Lu Y, Huang Q, Zhang C, Sun L, Ren C . Clinical Application Effects of Different Preoperative Blood Management Schemes in Older Patients with Delayed Intertrochanteric Fracture Surgery. Clin Interv Aging. 2022; 17:825-835. PMC: 9129265. DOI: 10.2147/CIA.S362020. View